AAIC 2026 showcases significant advances in Alzheimer's disease and dementia therapeutics, with emerging targets in four key areas: neuroinflammation modulation, synaptic function preservation, metabolic approaches, and gene therapy. These novel mechanisms represent the next frontier in disease-modifying therapies beyond anti-amyloid approaches.
The therapeutic pipeline at AAIC 2026 demonstrates a maturation of the field beyond amyloid-targeting strategies. While anti-amyloid antibodies like lecanemab and donanemab continue to generate real-world data, the conference highlights a broader portfolio of targets addressing multiple pathological hallmarks of neurodegenerative diseases[1].
Microglial cells, the resident immune cells of the brain, have emerged as critical players in Alzheimer's disease pathogenesis. At AAIC 2026, several programs target microglial signaling pathways:
TREM2 Signaling Pathway:
The triggering receptor expressed on myeloid cells 2 (TREM2) represents one of the most promising microglial targets. TREM2 variants significantly increase Alzheimer's disease risk, and therapeutic agonism of TREM2 may restore beneficial microglial functions[2].
Key Programs at AAIC 2026:
| Program | Mechanism | Company | Stage |
|---|---|---|---|
| AL002 | TREM2 agonist | Alector/GSK | Phase II |
| SAR-443122 | TREM2 inverse agonist | Sanofi | Phase I |
The neuroinflammatory cascade in Alzheimer's involves multiple signaling pathways:
Cytokine-targeted approaches:
Synaptic loss correlates most strongly with cognitive decline in Alzheimer's disease, making synaptic protection a critical therapeutic goal. AAIC 2026 highlights several approaches:
Key targets for synaptic preservation:
| Target | Function | Therapeutic Approach |
|---|---|---|
| PSD-95 | postsynaptic scaffold | Stabilization compounds |
| Synapsin | vesicle regulation | Phosphorylation modulators |
| NMDA receptor | calcium influx | Partial agonists |
| AMPA receptor | fast excitatory transmission | Positive allosteric modulators |
The synaptic dysfunction pathway involves multiple molecular steps that can be targeted therapeutically:
Amyloid-beta oligomer effects on synapses:
Tau-mediated synaptic dysfunction:
Therapeutic strategies:
Cerebral hypometabolism is an early feature of Alzheimer's disease, and metabolic approaches aim to restore brain energy homeostasis. AAIC 2026 features programs targeting:
NAD+ Metabolism:
Nicotinamide adenine dinucleotide (NAD+) depletion occurs in aging and Alzheimer's brain. NAD+ precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are being investigated[3].
Mitochondrial Function:
Astrocyte-Neuron Metabolic Coupling:
The astrocyte-neuron metabolic coupling pathway represents an emerging target:
| Approach | Mechanism | Stage |
|---|---|---|
| NAD+ precursors | Restore cellular energy | Phase II |
| Mitolytics | Clear damaged mitochondria | Preclinical |
| Glycolysis enhancers | Improve glucose utilization | Phase I |
Gene therapy for neurodegenerative diseases has matured significantly, with multiple programs advancing to clinical stages. AAIC 2026 highlights include:
AAV gene therapy for CNS disorders has made major advances:
Key developments:
| Target | Disease | Vector | Company |
|---|---|---|---|
| GBA1 | PD/Gaucher | AAV | Prev Ambrosia/Spark |
| LRRK2 | Parkinson's | AAV | Multiple |
| APOE4 | Alzheimer's | AAV | Voyager |
CRISPR gene editing technologies are advancing toward clinical application:
ASO technology has shown success in neurological diseases:
AAIC 2026 features updates from multiple late-stage clinical trials:
Phase III Programs:
Phase II Programs:
Phase I Programs:
The therapeutic landscape at AAIC 2026 demonstrates a maturing field moving toward multi-target approaches: